Effect of hyperbaric oxygen therapy on a murine squamous cell carcinoma model

Abstract

This study suggests that HBO therapy does accelerate the growth of microscopic foci of SCCs. This finding differs from some earlier studies and warrants further study.

Optical Imaging of Tumor Response to Hyperbaric Oxygen Treatment and Irradiation in an Orthotopic Mouse Model of Head and Neck Squamous Cell Carcinoma

“…In mammary and glioma tumor models, growth-inhibiting and anti-angiogenic effects were reported using a HBOT schedule of 3 to 4 sessions per week [ 13 , 14 , 48 ]. Studies using squamous cell cancer models did not reveal effects of HBOT on tumor growth [ 16 – 20 ], except for a recent study by Paniello et al [ 21 ] who also observed enhanced growth of xenografted HNSCC tumors in mice. In these studies, daily HBOT sessions were applied, according to the clinically used protocols for the management of radiation-induced injury.…”

“…In most studies in which subcutaneously implanted squamous carcinoma cell lines in mice were used, no differences in growth between control and HBOT groups were seen [ 16 – 20 ]. However, in a recent study, Paniello et al [ 21 ] reported enhanced growth of HNSCC tumor cells in C3H mice after HBOT. These divergent outcomes suggest that the choice of the experimental model, regarding cancer cell type, tumor location, or HBOT protocol, is critical for the proper determination of tumor responses to HBOT.…”

Effects of hyperbaric oxygen treatment on gastric cancer cell line SGC7901

“…A combinatorial approach using chemotherapeutic drugs with HBO may enhance sensitivity of tumor cells to chemotherapeutic agents (6,7) and the application of HBO in chemotherapy for malignant lymphoma, brain tumor, lung cancer, gastric cancer and breast cancer may increase chemotherapeutic efficacy while decreasing treatment related toxicity (8). However, HBO treatment alone may stimulate the proliferation of tumor tissues (9). Other studies indicate that cancer cells in hypoxic conditions are more likely to metastasize and thus be more deadly (10)(11)(12).…”

Leveraging immune memory against measles virus as an antitumor strategy in a preclinical model of aggressive squamous cell carcinoma

“…C3H/He mice engrafted with SCCVII cells are a well-established model of an aggressively growing tumor 8 with low immunogenicity. 16 Yet our data demonstrate that a re-called immune memory against a few MeV CTL and T-helper epitopes could be harnessed to effectively control tumor outgrowth and achieved a significant survival benefit following delivery of mRNA encoding the cognate epitopes directly into the tumor mass.…”

“…For tumor challenge experiments, mice were intradermally injected with syngeneic tumor cells (SCCVII) 8 that had been engineered to express the MeV cognate antigens or not. Where indicated, mice were injected intraperitoneally with a CD8-depleting antibody (clone YTS 169.4, BioXCell) 1 day prior to tumor injection (day −1), and at days 3 and 7 post-tumor injection.…”